The authors framed their report as a guidebook to help regulatory agencies across the globe coordinate "consistent" rules while allowing for societal differences.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The firms will continue to develop strains of algae that demonstrate improved photosynthetic efficiency and oil production.
Researchers uncover anti-CRISPR proteins that could help genetic engineering to be safer.
In PNAS this week: deep phenotyping of xeroderma pigmentosum, role of PREX2 mutations in melanoma development, and more.
Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.
The recent funding round follows $25 million that the company raised in January 2010.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
The drug maker Daiichi Sankyo will use Gene Bridges' DNA recombination technology.
University of Illinois at Urbana-Champgain, 23andMe, Michael J. Fox Foundaton for Parkinson's Research, Parkinson's Institute and Clinical Center, SeqWright, Roche NimbleGen, Chronix Biomedical, Genome Atlantic, Agilent Technologies
In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.
An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.
The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.
For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.